Key Takeaway: Vor Bio announced its participation in the Stifel 2025 Virtual Immunology and Inflammation Forum, which includes a fireside chat and virtual investor meetings. The event is scheduled for September 15, 2025, and will highlight Vor Bio's advancements in autoimmune disease treatment. The company is currently progressing its drug, telitacicept, through Phase 3 clinical development. The presentation will be available for live streaming and on-demand access through the company's website.
Price reaction · baseline $36.3 (2025-09-11 close) · hit after-hours · 1 other VOR headline(s) in the window, move may be shared
day 0 close · peak
-4.1%
Market Sentiment Analysis
POSITIVE FACTORS
Vor Bio is actively participating in important industry forums.
The company is focusing on advancing its innovative treatment for autoimmune diseases.
Engagement with investors through virtual meetings demonstrates a proactive approach.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+442%
120-day peak, hindsight
Typical move
18.8%
average across 6 past catalysts
Cash runway
~55 mo
Minimal dilution risk
Lead asset
Telitacicept
Phase 3 · Primary Sjogren's Disease
Full Press Release Details
CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Stifel 2025 Virtual Immunology and Inflammation Forum.
Fireside Chat: Monday, September 15, 2025 at 4:00-4:25 pm ET in Track 1
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.
Media & Investor Contacts:
Frequently Asked Questions
What event will Vor Bio participate in on September 15, 2025?
Vor Bio will take part in the Stifel 2025 Virtual Immunology and Inflammation Forum.
What is telitacicept used for?
Telitacicept is a novel dual-target fusion protein aimed at treating autoimmune diseases.
Where can I watch the fireside chat?
The fireside chat can be viewed live and in replay on Vor Bio's website.
When is Vor Bio's fireside chat scheduled?
The fireside chat is scheduled for September 15, 2025, from 4:00-4:25 pm ET.
How is Vor Bio advancing its treatments?
Vor Bio is focused on rapidly advancing telitacicept through Phase 3 clinical development.